General Bio focuses on developing health functional food and cosmetics to maintain health and beauty. The company leads the research and development of bio-convergence, nano-technology, polymer technology, and new bio-materials. General Bio has complied with social and environmental responsibilities to address problems caused by hazardous chemical products and upheld corporate ethics to preserve local ecosystems. The company is developing eco-friendly raw materials and sustainable products. General Bio only uses safe raw materials that have been registered with WHO and the EPA to perform extractions on a variety of natural materials, evaluate their functional properties, and manufacture products

By incubating these young companies, General Bio is treading on the path to create a positive influence and cultivate a healthy corporate culture

—Jeong Hun Seo, CEO

GenFleet Therapeutics is a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology. GenFleet Therapeutics has created industry-leading capabilities and expertise in developing novel drug candidates, including small molecules and biologics. The company has over ten programs in development, of which several have entered clinical stages. GenFleet’s rich pipeline is focused on target innovation and drug development that is driven by biological mechanism research. The company has constructed its proprietary R&D platform based on an in-depth understanding of disease biology, and translational medicine, along with the research into the latest biological mechanism of cancer pathways, tumor microenvironment, and human immunoregulation.

The clinical-stage bio-venture company has been conducting an array of unique drug development with ground-breaking expertise in solute carrier (SLC) transporters. SLCs—metabolic gatekeepers of cells—play a vital role in mediating the transportation of essential amino acids while also being a novel class of tumor suppressors. While LAT1 is highly expressed in cancer and immune cells, J-Pharma is undertaking the clinical development of two small compounds, selectively targeting LAT1: JPH203 for the treatment of BTC and OKY-034 for pancreatic cancers and multiple sclerosis (MS). These potent LAT1 inhibitors instantly thwart the supply of essential amino acids to tumor cells

Taking LAT1 as the novel drug target, we are striving to achieve our pipe dream of treating highly complex disorders in liaison with cutting-edge academic institutions

—Max Yoshitake, President & CEO

A therapeutics solutions provider that offers a Cell-Derived-Vesicle based drug delivery platform—BioDrone®. A unique drug delivery system, the device can deliver specialized drugs and other chemical substances used in therapeutic treatment directly to cells. Currently, BioDrone is in the ongoing clinical trial phase at many pharma and biotech partner companies. A significant advancement of MDimune is its proprietary extrusion process to grab cells and pass them through small filter membranes, making them size appropriate for exosome extraction. Once the required numbers of vesicles are collected, the CDVs can be modified to add various drugs, including gene cargos, RNAs, proteins or even DNA inside or on top of the vesicles.

Our BioDrone platform will enable highly targeted drug delivery to specific lesions or abrasions, allowing for treatment with minimum side effects and maximum efficacy of the drugs eventually

—Seung Wook Oh, Chief Scientific Officer

Anticancer Bioscience develops synthetic lethal therapies that address the unmet medical needs of cancer patients. The company is a growing precision therapeutics firm headquartered in Chengdu, China, with global research and development teams in India, the United Kingdom, and the United States. Its most advanced programs are synthetic lethal therapies for cancer. Genetic perturbations that fuel cancer growth can also introduce an over-dependence for the cancer cell on pathways and proteins that the normal, non-cancerous cell does not have. Anticancer Bioscience was founded by scientists that are experts in identifying and exploiting these cancer vulnerabilities.

bitBiome efficiently acquires complete genome sequences of microorganisms using its unique single-cell genome analysis technology bit-MAP®. bitBiome, Inc. has been sequencing genomic data of all microorganisms on the planet at the highest resolution to ‘renovate’ every industry. The company builds a microbial genetic database that surpasses others in both quality and quantity to create an innovative data-driven bio-production platform in collaboration with industrial partners.

EDIGENE is a clinical-stage global biopharmaceutical company focusing on the transformation of gene-editing technology. It is committed to developing innovative treatments for intractable genetic diseases and cancers. The company’s LEAPER ™ is the programmed editing of RNA using endogenous ADAR (ADAR is the abbreviation of Adenosine Deaminase Acting on RNA, that is, RNA adenosine deaminase). This technology utilizes the natural mechanism in the cell, just by transferring a specially designed "guide" RNA, it can produce efficient and precise editing of specific nucleotides on the target RNA by recruiting endogenous proteins in the cell, without the need to introduce any exogenous effector protein.

Heartseed transforms the treatment of severe heart failure by delivering cardiac regenerative medicine. Heartseed is a bio-venture that challenges heart failure, which had only been treated by transplantation surgery, from the approach of the practical application of treatment using iPS cells, and opens up a completely new treatment method. As a result of gathering various human resources and knowledge and continuing various challenges, the company has overcome many challenges toward the practical application of treatment using iPS cells and stably cultivating high-quality cardiomyocytes.

JW Therapeutics is an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy products. Founded in 2016, JW Therapeutics is committed to becoming an innovation leader in cell immunotherapy. The company has built a top world-class platform for technology and product development in cell immunotherapy, as well as a promising product pipeline covering both hematologic malignancies and solid tumors, to bring the hope of a cure for Chinese and global patients, and to lead the healthy and standardized development of China’s cell immunotherapy industry.

MabGenesis Inc. is a biopharmaceutical startup that uses 30+ years of antibody research to provide first-in-class and best-in-class therapeutic monoclonal antibody drugs for humans and animals. The company has the world’s highest quality antibody libraries (MOURA Libraries) in terms of functionality and completeness, as well as highly efficient monoclonal antibody isolation technology (IMPACT). By using these, the company makes it possible to obtain quality monoclonal antibodies that recognize unique 3D structures or subtle structural differences of target molecules such as membrane proteins, thus contributing to new drug development opportunities in the pharmaceutical industry.